MCID: IMP006
MIFTS: 43

Impulse Control Disorder

Categories: Mental diseases

Aliases & Classifications for Impulse Control Disorder

MalaCards integrated aliases for Impulse Control Disorder:

Name: Impulse Control Disorder 12 15
Disruptive, Impulse Control, and Conduct Disorders 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:10937
ICD9CM 36 312.30
MeSH 45 D007174
NCIt 51 C34723
SNOMED-CT 69 66347000
ICD10 34 F63.9
UMLS 74 C0021122

Summaries for Impulse Control Disorder

Disease Ontology : 12 A disease of mental health that involves a failure to resist an impulsive act or behaviour that may be harmful to self or others.

MalaCards based summary : Impulse Control Disorder, also known as disruptive, impulse control, and conduct disorders, is related to oppositional defiant disorder and trichotillomania. An important gene associated with Impulse Control Disorder is ANKK1 (Ankyrin Repeat And Kinase Domain Containing 1), and among its related pathways/superpathways are Dopamine-DARPP32 Feedback onto cAMP Pathway and Circadian rythm related genes. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Impulse-control disorder (ICD) is a class of psychiatric disorders characterized by impulsivity –... more...

Related Diseases for Impulse Control Disorder

Diseases related to Impulse Control Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 oppositional defiant disorder 32.1 DRD2 DRD4
2 trichotillomania 32.0 CLNK DLGAP3 SLITRK1
3 pathological gambling 31.6 DRD2 DRD3 DRD4
4 alexithymia 30.0 ANKK1 DRD2
5 restless legs syndrome 29.9 DRD2 DRD3
6 gilles de la tourette syndrome 29.8 DRD2 DRD4 SLITRK1
7 obsessive-compulsive disorder 29.2 DLGAP3 DRD2 DRD3 DRD4 SLITRK1
8 substance abuse 29.2 DRD2 DRD3 DRD4
9 kleptomania 11.5
10 pyromania 11.3
11 intermittent explosive disorder 11.0
12 kluver-bucy syndrome 11.0
13 parkinson disease, late-onset 10.5
14 telogen effluvium 10.2 DLGAP3 SLITRK1
15 taqi polymorphism 10.2 ANKK1 DRD2
16 follicular mucinosis 10.1 DLGAP3 SLITRK1
17 antisocial personality disorder 10.1 ANKK1 DRD2
18 stereotypic movement disorder 10.1 CLNK SLITRK1
19 pituitary adenoma, prolactin-secreting 10.1
20 depression 10.1
21 rem sleep behavior disorder 10.0
22 heroin dependence 10.0 ANKK1 DRD2 DRD4
23 personality disorder 10.0 ANKK1 DRD2 DRD4
24 tic disorder 10.0 DRD2 DRD4 SLITRK1
25 bipolar disorder 10.0
26 polysubstance abuse 9.9 DRD2 DRD3
27 tardive dyskinesia 9.9 DRD2 DRD3
28 conduct disorder 9.9 DRD2 DRD4
29 bruxism 9.9 DRD2 DRD3
30 opiate dependence 9.8 DRD2 DRD3
31 perry syndrome 9.8
32 tobacco addiction 9.8
33 dystonia 3, torsion, x-linked 9.8
34 frontotemporal dementia 9.8
35 anxiety 9.8
36 smoking as a quantitative trait locus 3 9.8
37 burns 9.8
38 diabetes mellitus 9.8
39 withdrawal disorder 9.8
40 basal ganglia calcification 9.8
41 stuttering 9.8
42 social phobia 9.8
43 patulous eustachian tube 9.8
44 dementia 9.8
45 premature ejaculation 9.8
46 bipolar i disorder 9.8
47 epilepsy 9.8
48 dermatitis 9.8
49 movement disease 9.8
50 dystonia 9.8

Comorbidity relations with Impulse Control Disorder via Phenotypic Disease Network (PDN):


Schizophreniform Disorder

Graphical network of the top 20 diseases related to Impulse Control Disorder:



Diseases related to Impulse Control Disorder

Symptoms & Phenotypes for Impulse Control Disorder

GenomeRNAi Phenotypes related to Impulse Control Disorder according to GeneCards Suite gene sharing:

27 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.6 DRD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.6 DRD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.6 CLNK DRD3 DRD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.6 DRD3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.6 CLNK
6 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.6 DRD3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.6 DRD3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.6 DRD3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.6 DRD4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.6 CLNK
11 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.6 DRD3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.6 DRD3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.6 CLNK
14 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.6 DRD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.6 DRD3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.6 CLNK
17 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.6 DRD3

Drugs & Therapeutics for Impulse Control Disorder

Drugs for Impulse Control Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Nicotine Approved Phase 4,Phase 2,Not Applicable 54-11-5 89594 942
4
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
5
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
6
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 16590-41-3 5360515
7
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
8
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
9
Carbidopa Approved Phase 4 28860-95-9 34359
10
Levodopa Approved Phase 4,Phase 3 59-92-7 6047
11
Sertraline Approved Phase 4,Phase 2 79617-96-2 68617
12
Citalopram Approved Phase 4 59729-33-8 2771
13
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
14
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
15
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
16
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
17
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
18
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
19 Dopamine Uptake Inhibitors Phase 4,Phase 2,Not Applicable
20 Central Nervous System Stimulants Phase 4,Phase 2
21 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
24 Nicotinic Agonists Phase 4,Phase 2
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Autonomic Agents Phase 4,Phase 3,Phase 2
27 Cholinergic Agents Phase 4,Phase 2
28 Hypoglycemic Agents Phase 4,Phase 2
29 Anticonvulsants Phase 4,Phase 2
30 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Dopamine agonists Phase 4,Phase 3,Phase 2,Not Applicable
33 Sympathomimetics Phase 4,Phase 3,Phase 2
34 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Cardiotonic Agents Phase 4,Phase 3,Phase 2
36 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
37 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
39 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
40 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Antidepressive Agents Phase 4,Phase 2,Not Applicable
42 Parasympatholytics Phase 4
43 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Not Applicable
44 Muscarinic Antagonists Phase 4
45 Cholinergic Antagonists Phase 4
46 Neuroprotective Agents Phase 4
47 Monoamine Oxidase Inhibitors Phase 4
48 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
50 Antiemetics Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 176)
# Name Status NCT ID Phase Drugs
1 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
2 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4 nicotine patch;placebo
3 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
4 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
5 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Completed NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg);Dopaminergic Agonists
6 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4 Sertraline
7 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4 Escitalopram
8 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
9 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
10 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) Completed NCT00321854 Phase 4 pramipexole
11 Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression Completed NCT01078298 Phase 4 varenicline;placebo
12 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
13 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
14 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
15 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
16 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
17 A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients Completed NCT01631825 Phase 3 SPM 962
18 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
19 Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Completed NCT02242487 Phase 3 CVT-301
20 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
21 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
22 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
23 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
24 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders Recruiting NCT03146130 Phase 3
25 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
26 Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors Recruiting NCT03530800 Phase 2, Phase 3 Dronabinol;Placebo
27 Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Stimulation Recruiting NCT03669315 Phase 3
28 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Unknown status NCT02934919 Phase 2 Nalmefene
29 Testing a New Therapy for Trichotillomania Unknown status NCT00872742 Phase 2
30 Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Unknown status NCT01340274 Phase 2
31 Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling Unknown status NCT01529047 Phase 2
32 Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients Completed NCT02599753 Phase 2 18-FDTBZ
33 Double-Blind Naltrexone in Compulsive Sexual Behavior Completed NCT00467558 Phase 2 Naltrexone;Sugar pill
34 Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET Completed NCT02039024 Phase 2 18F- DTBZ
35 N-Acetyl Cysteine in Pathologic Skin Picking Completed NCT01063348 Phase 2 N-Acetyl Cysteine;Placebo
36 Inositol in Trichotillomania Completed NCT01875445 Phase 2 Inositol;Placebo
37 A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome Completed NCT01562743 Phase 2 SPM 962
38 The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Completed NCT00464737 Phase 2 Rotigotine;Rotigotine
39 A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease Completed NCT02818777 Phase 2 cannabidiol
40 Memantine in the Treatment of Kleptomania Completed NCT00880685 Phase 2 Memantine
41 Double-Blind Naltrexone in Kleptomania Completed NCT00332579 Phase 2 Naltrexone;Placebo
42 A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED Completed NCT00127400 Phase 2
43 A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder Completed NCT00078754 Phase 2 Fluoxetine;Divalproex;Placebo
44 Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder Completed NCT02055638 Phase 1, Phase 2 SRX246;Placebo
45 Psychotherapy for Intermittent Explosive Disorder Completed NCT00667212 Phase 2
46 Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Completed NCT03223896 Phase 2 Naloxone hydrochloride 20mg/ml
47 D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Completed NCT02203786 Phase 2 Haloperidol;Fluphenazine;Dexedrine;Placebo
48 Trichotillomania: Group Cognitive-Behavioral Therapy Completed NCT01968343 Phase 2
49 Topiramate Trial for Pathological Gamblers Completed NCT01843699 Phase 2 Topiramate flexible dosage;Placebo matching tablets
50 Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania Completed NCT01654523 Phase 2

Search NIH Clinical Center for Impulse Control Disorder

Cochrane evidence based reviews: disruptive, impulse control, and conduct disorders

Genetic Tests for Impulse Control Disorder

Anatomical Context for Impulse Control Disorder

MalaCards organs/tissues related to Impulse Control Disorder:

42
Testes, Brain, Skin, Pituitary, Liver, Eye, Cortex

Publications for Impulse Control Disorder

Articles related to Impulse Control Disorder:

(show top 50) (show all 58)
# Title Authors Year
1
Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. ( 30361296 )
2019
2
Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder. ( 29066517 )
2018
3
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. ( 29198499 )
2018
4
Compulsive Sexual Behavior as an Impulse Control Disorder: Awaiting Field Studies Data. ( 29572770 )
2018
5
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. ( 29753604 )
2018
6
A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease. ( 30054182 )
2018
7
Sleep in Parkinson's Disease with Impulse Control Disorder. ( 30099617 )
2018
8
Impulse Control Disorder in Parkinson's Disease: A Meta-Analysis of Cognitive, Affective, and Motivational Correlates. ( 30233478 )
2018
9
Disruption of Multiple Distinctive Neural Networks Associated With Impulse Control Disorder in Parkinson's Disease. ( 30519167 )
2018
10
Impulse control disorder, lysosomal malfunction and ATP13A2 insufficiency in Parkinsonism. ( 27997702 )
2017
11
A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease. ( 28288482 )
2017
12
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. ( 28346715 )
2017
13
ISMP Adverse Drug Reactions: Pregabalin-Induced Stuttering Nitroglycerine-Induced Bradycardia Progressing to Asystole Minocycline-Induced DRESS Leading to Liver Transplantation and Type 1 Diabetes Increased Risk of Vertebral Fractures in Women Receiving Thiazide or Loop Diuretics Gambling Disorder and Impulse Control Disorder with Aripiprazole. ( 28515502 )
2017
14
Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. ( 28767029 )
2017
15
Electro-acupuncture treatment for internet addiction: Evidence of normalization of impulse control disorder in adolescents. ( 28861803 )
2017
16
Impulse control disorder and response-inhibition alterations in Parkinson's disease. A rare case of totally absent functionality of the medial-prefrontal cortex and review of literature. ( 29034115 )
2017
17
Depression, Impulse Control Disorder, and Life Style According to Smartphone Addiction. ( 29295357 )
2017
18
Problematic Mobile Gaming in Parkinson's Disease: An Impulse Control Disorder for the Smartphone. ( 30838269 )
2017
19
Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. ( 27930495 )
2017
20
Impaired learning of punishments in Parkinson's disease with and without impulse control disorder. ( 27848033 )
2017
21
Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease. ( 27087472 )
2017
22
Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. ( 26534930 )
2016
23
Psychosis and concurrent impulse control disorder in Parkinson's disease: A review based on a case report. ( 29213446 )
2016
24
Tattooing as a Symptom of Impulse Control Disorder in a Parkinsonian Patient With Pramipexole. ( 27749676 )
2016
25
18F-FDG-PET Correlates of Impulse Control Disorder in a Diabetic Patient. ( 27697074 )
2016
26
Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. ( 27425586 )
2016
27
Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome? ( 27264342 )
2016
28
Repetitive urges to inflict burns: An unusual presentation of impulse control disorder. ( 28163418 )
2016
29
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse. ( 25362251 )
2015
30
The addiction-related gene ANKK1 in Parkinsonian patients with impulse control disorder. ( 25447970 )
2015
31
Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. ( 25645960 )
2015
32
Pet killing as a manifestation of impulse control disorder secondary to pramipexol. ( 25768852 )
2015
33
Impulse control disorder manifesting as hidden sexual self-injury. ( 25828732 )
2015
34
Idiopathic Basal Ganglia Calcification Presented with Impulse Control Disorder. ( 26246920 )
2015
35
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. ( 24434037 )
2014
36
Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease. ( 25283069 )
2014
37
Pathological generosity: an atypical impulse control disorder after a left subcortical stroke. ( 23962063 )
2014
38
Impulse control disorder in a patient with X-linked dystonia-parkinsonism after bilateral pallidal deep brain stimulation. ( 23920134 )
2013
39
Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. ( 24045609 )
2013
40
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. ( 23472375 )
2013
41
The role of self-awareness and cognitive dysfunction in Parkinson's disease with and without impulse-control disorder. ( 23686032 )
2013
42
Zoophilia and impulse control disorder in a patient with Parkinson disease. ( 22057400 )
2012
43
Comorbid impulse control disorder in bipolar disorder: the role of antidepressants. ( 22423377 )
2012
44
Is premature ejaculation an impulse control disorder? ( 22543077 )
2012
45
Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. ( 23123689 )
2012
46
Tourette's disease with impulse control disorder. ( 21431012 )
2011
47
Dermatitis artefacta in a patient affected by impulse control disorder: case report. ( 21489363 )
2011
48
Impulse control disorder comorbidity among patients with bipolar I disorder. ( 21683175 )
2011
49
Impulse control disorder and piribedil: report of 5 cases. ( 19959959 )
2010
50
Pathological gambling: an impulse control disorder? Measurement of impulsivity using neurocognitive tests. ( 20803888 )
2010

Variations for Impulse Control Disorder

Expression for Impulse Control Disorder

Search GEO for disease gene expression data for Impulse Control Disorder.

Pathways for Impulse Control Disorder

GO Terms for Impulse Control Disorder

Cellular components related to Impulse Control Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 9.32 DRD2 DRD3
2 integral component of postsynaptic density membrane GO:0099061 9.26 DRD3 SLITRK1
3 dopaminergic synapse GO:0098691 9.16 DRD2 DRD3
4 GABA-ergic synapse GO:0098982 9.13 DRD2 DRD3 SLITRK1
5 glutamatergic synapse GO:0098978 9.02 DLGAP3 DRD2 DRD3 DRD4 SLITRK1

Biological processes related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 synapse assembly GO:0007416 9.65 DRD2 SLITRK1
2 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.65 DRD2 DRD3
3 circadian regulation of gene expression GO:0032922 9.65 DRD2 DRD3
4 negative regulation of protein kinase B signaling GO:0051898 9.64 DRD2 DRD3
5 social behavior GO:0035176 9.64 DRD3 DRD4
6 visual learning GO:0008542 9.63 DRD2 DRD3
7 response to cocaine GO:0042220 9.63 DRD2 DRD3
8 positive regulation of cytokinesis GO:0032467 9.62 DRD2 DRD3
9 response to morphine GO:0043278 9.62 DRD2 DRD3
10 adult behavior GO:0030534 9.61 DRD2 SLITRK1
11 negative regulation of blood pressure GO:0045776 9.61 DRD2 DRD3
12 response to amphetamine GO:0001975 9.61 DRD2 DRD3 DRD4
13 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.6 DRD2 DRD3
14 synaptic transmission, dopaminergic GO:0001963 9.59 DRD2 DRD3
15 prepulse inhibition GO:0060134 9.58 DRD2 DRD3
16 positive regulation of renal sodium excretion GO:0035815 9.58 DRD2 DRD3
17 arachidonic acid secretion GO:0050482 9.58 DRD2 DRD3 DRD4
18 G protein-coupled receptor internalization GO:0002031 9.57 DRD2 DRD3
19 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.56 DRD3 DRD4
20 behavioral response to ethanol GO:0048149 9.55 DRD2 DRD4
21 negative regulation of voltage-gated calcium channel activity GO:1901386 9.54 DRD2 DRD4
22 behavioral response to cocaine GO:0048148 9.54 DRD2 DRD3 DRD4
23 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.52 DRD2 DRD3
24 negative regulation of dopamine receptor signaling pathway GO:0060160 9.51 DRD2 DRD3
25 dopamine receptor signaling pathway GO:0007212 9.5 DRD2 DRD3 DRD4
26 acid secretion GO:0046717 9.49 DRD2 DRD3
27 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
28 regulation of locomotion involved in locomotory behavior GO:0090325 9.46 DRD2 DRD3
29 negative regulation of protein secretion GO:0050709 9.43 DRD2 DRD3 DRD4
30 dopamine metabolic process GO:0042417 9.33 DRD2 DRD3 DRD4
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD2 DRD3 DRD4
32 response to histamine GO:0034776 8.8 DRD2 DRD3 DRD4

Molecular functions related to Impulse Control Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.43 DRD2 DRD3 DRD4
2 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
3 adrenergic receptor activity GO:0004935 9.32 DRD2 DRD3
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4

Sources for Impulse Control Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....